News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What makes you think it's unlikely? I don't know what factors are taken into consideration when deciding what should be covered by insurance codes. However, we know that Vizient, the American Medical Association, and the Journal of the American Heart Association all seem to be taking Cardio Diagnostics pretty seriously at this point.
Insurance code approval would send this to the moon. But as you state the approval may not go through. Still, I'm thinking at a minimum they are a prime buyout candidate.
As far as their earnings go, they should already be making money as of November 1st due to the Vizient contract. They may need to dilute but I don't think it'll be very much, maybe $10 million? Whatever dilution takes place would quickly get absorbed given all they have going for them right now. I'm not worried
He's the Chief Medical Officer of the company. He'd be saying that whether he owned shares or not. Btw his position isn't even that big.
"Because the PrecisionCHD test requires only a simple blood draw, patients in underserved areas will now have access to state-of-the-art cardiac assessments.
PrecisionCHD's ability to be administered in primary care or telemedicine settings significantly reduces the need for patients from rural communities to travel to distant specialized clinics. This accessibility marks a step towards mitigating healthcare disparities, especially in rural areas with limited resources and infrastructure."
"this is a game changer for Personalized Cardiovascular Care" and noted that "unlike other methods of CHD testing, there is no exposure of patients to ionizing radiation or potentially kidney damaging contrast dye."..........Dr. Philibert added, "What's truly revolutionary about this approach is its ability to provide a more comprehensive, personalized snapshot of a patient's CHD drivers, allowing for early intervention and tailored treatment plans. This is personal for me; seeing patients who previously had limited options for early diagnosis now have access to this state-of-the-art technology is a milestone in cardiac care."
its a lot easier to fail than succeed so the odds are stacked ..we shall see
all of that could be or is true but i am only concerned about the mkt the total public bet.. notwithstanding the revenue stream not there yet i think it will be ..that this will be a low overhead cash monster as well as a "significant leap forward" in preventive cardio care
i have to trust myself ... i think what they own is worth billions. wheres the revenue.... today.... ..tomorrow?!!!.. a nearly billion shares traded over th last couple of weeks...and still it moves on a whisper
there are going to be competitors but first come first serve and the vizient and now India .....ithe JAHA art. etc.. if this becomes theeeee platform. with a potential mkt of the whole world.!!!!! i will hang around a while to see if it works out that way.
no dillution here either....they wont dillute till double digits...this is mongacious..it really is just an opinion
no short covering yet.. and the long term view gets better and better
bustin out!!
still moves at a whisper.. any dilution will be well north of here or we would have seen it already. and would just be equity added anyway.. MKT CAP... i say at least one billion added shares... added equity.. adelante
was able to add 100 shares in the 1.8 range. im so stoked about this one. if it flops ill be freaking bummed out big time.. but i think its going to be mongacious
stock of the decade...in its infancy...
billion dollar cap on the way. i said so....for what its worth.. glta
|
Followers
|
16
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
349
|
|
Created
|
01/06/23
|
Type
|
Free
|
| Moderators | |||
